EYLEA® in the treatment of macular oedema secondary to Hemiretinal Vein Occlusion (HRVO)
EYLEA is used to treat macular oedema secondary to Hemiretinal Vein Occlusion (HRVO)
Your doctor has prescribed EYLEA because you have been diagnosed with macular oedema secondary to hemiretinal vein occlusion, or HRVO.
This site also contains an audio with all of the information contained in this written information.
Whether you read this guide or choose to listen to it, it has been made to help answer any questions you may have, so you can get the most out of your treatment.
Audio Patient Guide
Safety Information
Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form, which is available online at http://www.medicinesauthority.gov.mt/adrportal, and sent by post or email to:
P: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000
E: postlicensing.medicinesauthority@gov.mt or E: pv@alfredgera.com
Date of Preparation: April 2026
MA-EYL-MT-0029-1
